This tranche was dominated by a new investment from Baxter International to go along with the September 2008 investments by new investors Genzyme Ventures and Mitsubishi UFJ Capital.
Additional participants in the round also include MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Ventures, Singapore Bio-Innovations, and 5AM Ventures.
David Pritchard, president and CEO of KaloBios, said: “We are very pleased to add significantly to this financing round in a very challenging environment. This achievement reflects our investors’ appreciation of the value that we have built with our two Phase II, potential first-in-class human antibody therapeutics programs that are focused on significant market opportunities.
“It also recognizes the strategic potential of our Humaneering technology for engineering potential best-in-class human antibody therapeutics for chronic diseases.”